Insights

Strategic Acquisition Inhibrx's recent acquisition by Sanofi for up to $2.2 billion indicates strong industry validation and a significant step towards expanding its pipeline and therapeutic offerings, presenting opportunities for partnership and licensing deals with larger pharmaceutical entities.

Collaborative Projects The company's active collaborations with NorthStar Medical Radioisotopes and Oxford Finance demonstrate openness to joint ventures and funding opportunities, which could be leveraged to develop new radiopharmaceuticals or secure financial support for upcoming research programs.

Innovative Technology Inhibrx’s focus on single domain antibody platform and multivalent multispecific formats positions it as a leader in biotech innovation, offering potential sales avenues for custom biologic therapeutics and targeted drug delivery solutions to biopharma companies seeking cutting-edge platforms.

Growing Financials With recent funding of approximately $150 million and revenue between $1 million and $10 million, the company is in a growth phase, making it an attractive partner or customer for clinical trial contracts, research services, and biological capabilities expansion.

Industry Relevance Aligned with major biotech firms like Genentech and Amgen, Inhibrx’s focus on oncology and rare diseases highlights opportunities to introduce specialized therapeutics and diagnostic tools tailored for clinical providers and specialty pharma companies in rapidly evolving markets.

Inhibrx Biosciences, Inc. Tech Stack

Inhibrx Biosciences, Inc. uses 8 technology products and services including WordPress, Twemoji, Benchling, and more. Explore Inhibrx Biosciences, Inc.'s tech stack below.

  • WordPress
    Content Management System
  • Twemoji
    Font Scripts
  • Benchling
    Health Platform
  • JSON-LD
    Javascript Frameworks
  • Preact
    Javascript Libraries
  • core-js
    Javascript Libraries
  • Microsoft
    Miscellaneous
  • HTTP/3
    Web & Portal Technology

Media & News

Inhibrx Biosciences, Inc.'s Email Address Formats

Inhibrx Biosciences, Inc. uses at least 1 format(s):
Inhibrx Biosciences, Inc. Email FormatsExamplePercentage
First@inhibrx.comJohn@inhibrx.com
81%
FirstL@inhibrx.comJohnD@inhibrx.com
11%
Last@inhibrx.comDoe@inhibrx.com
7%
First.L@inhibrx.comJohn.D@inhibrx.com
1%

Frequently Asked Questions

Where is Inhibrx Biosciences, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc.'s main headquarters is located at 11025 North Torrey Pines Road Suite 140 San Diego, California United States. The company has employees across 2 continents, including North AmericaEurope.

What is Inhibrx Biosciences, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Inhibrx Biosciences, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Inhibrx Biosciences, Inc.'s stock symbol?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc. is a publicly traded company; the company's stock symbol is INXB.

What is Inhibrx Biosciences, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc.'s official website is inhibrx.com and has social profiles on LinkedInCrunchbase.

What is Inhibrx Biosciences, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Inhibrx Biosciences, Inc. have currently?

Minus sign iconPlus sign icon
As of March 2026, Inhibrx Biosciences, Inc. has approximately 114 employees across 2 continents, including North AmericaEurope. Key team members include Chief Scientific Officer: C. B.Vice President - Medical Affairs And Business Development: R. B.Executive Director, Formulation And Drug Product Manufacturing: B. L.. Explore Inhibrx Biosciences, Inc.'s employee directory with LeadIQ.

What industry does Inhibrx Biosciences, Inc. belong to?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc. operates in the Biotechnology Research industry.

What technology does Inhibrx Biosciences, Inc. use?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc.'s tech stack includes WordPressTwemojiBenchlingJSON-LDPreactcore-jsMicrosoftHTTP/3.

What is Inhibrx Biosciences, Inc.'s email format?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc.'s email format typically follows the pattern of First@inhibrx.com. Find more Inhibrx Biosciences, Inc. email formats with LeadIQ.

How much funding has Inhibrx Biosciences, Inc. raised to date?

Minus sign iconPlus sign icon
As of March 2026, Inhibrx Biosciences, Inc. has raised $150M in funding. The last funding round occurred on Jan 13, 2025 for $150M.

When was Inhibrx Biosciences, Inc. founded?

Minus sign iconPlus sign icon
Inhibrx Biosciences, Inc. was founded in 2010.

Inhibrx Biosciences, Inc.

Biotechnology ResearchCalifornia, United States51-200 Employees

At Inhibrx, our mission is to deliver optimized, biologic therapeutics to people with life-threatening conditions. Toward this goal, we have built a large and diverse pipeline with the potential to impact cancer and orphan diseases through our single domain antibody platform technology. Single domain antibodies (sdAbs) provide a small, simple, modular target binding domain that can be combined in a variety of ways to meet specific needs of unique biological targets. Our sdAb-based therapeutic candidates have been designed to interface with the biology of each target antigen, and can be readily manufactured at high yields with established processes. We have created various multivalent and multispecific therapeutic formats that are each designed to achieve unique functions, including the ability to:

- effectively cluster receptors with precisely defined valency;
- simultaneously engage multiple antigens or epitopes;
- combine synergistic functions in a single molecule; and
- restrict therapeutic activity to the tumor microenvironment or other biologically distinct tissue.

Section iconCompany Overview

Headquarters
11025 North Torrey Pines Road Suite 140 San Diego, California United States
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
INXB
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2010
Employees
51-200

Section iconFunding & Financials

  • $150M

    Inhibrx Biosciences, Inc. has raised a total of $150M of funding over 6 rounds. Their latest funding round was raised on Jan 13, 2025 in the amount of $150M.

  • $1M$10M

    Inhibrx Biosciences, Inc.'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $150M

    Inhibrx Biosciences, Inc. has raised a total of $150M of funding over 6 rounds. Their latest funding round was raised on Jan 13, 2025 in the amount of $150M.

  • $1M$10M

    Inhibrx Biosciences, Inc.'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.